LY-404,187

LY-404,187

Systematic (IUPAC) name
N-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide
Clinical data
Legal status	Investigational New Medicine
Identifiers
CAS Number	211311-95-4 Y
ATC code	none
ChemSpider	18962921 N
Synonyms	LY-404,187; N-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide
Chemical data
Formula	C19H22N2O2S
Molecular mass	342.45 g/mol
SMILES N#Cc2ccc(cc2)-c1ccc(C(C)CNS(=O)(=O)C(C)C)cc1
InChI InChI=1S/C19H28N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-7,14-15,17,19,21H,8-11,13H2,1-3H3 N Key:AIALBPYHYGYYRB-UHFFFAOYSA-N N
NY (what is this?)  (verify)

LY-404,187 (or LY404187) is an ampakine (or "AMPA receptor potentiator") developed by Eli Lilly and Company. It is a member of the biarylpropylsulfonamide class of ampakines.

LY-404,187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting antidepressant action as well as having possible application in the treatment of schizophrenia, Parkinson's disease and ADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of BDNF in the brain. It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.